J Timothy Greenamyre

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8841390/publications.pdf

Version: 2024-02-01

212	27,877	5248 83	5663 162
papers	citations	h-index	g-index
221	221	221	19847
all docs	docs citations	times ranked	citing authors

#	ARTICLE	IF	CITATIONS
1	Preventing Parkinsonâ€™s Disease: An Environmental Agenda. Journal of Parkinson's Disease, 2022, 12, 45-68.	1.5	45
2	LRRK2 and idiopathic Parkinsonâ€™s disease. Trends in Neurosciences, 2022, 45, 224-236.	4.2	53
3	NADPH oxidase 2 activity in Parkinson's disease. Neurobiology of Disease, 2022, 170, 105754.	2.1	18
4	Vesicular glutamate transporter modulates sex differences in dopamine neuron vulnerability to ageâ€•related neurodegeneration. Aging Cell, 2021, 20, e13365.	3.0	20
5	VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration. Journal of Neuroscience, 2021, 41, 4937-4947.	1.7	17
6	The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease. Neurobiology of Disease, 2021, 153, 105312.	2.1	28
7	LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease. Neurobiology of Disease, 2020, 134, 104626.	2.1	73
8	Î±-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo. Redox Biology, 2020, 37, 101695.	3.9	26
9	Acquired dysregulation of dopamine homeostasis reproduces features of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 34.	2.5	29
10	Protection from Î±-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20. Npj Parkinson's Disease, 2020, 6, 38.	2.5	21
11	Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson's disease. Environmental Sciences: Processes and Impacts, 2020, 22, 543-554.	1.7	29
12	Response to Rotenone and Parkinsonâ€™s Disease; Reduced Sensitivity in Females. Toxicological Sciences, 2019, 170, 563-563.	1.4	3
13	Sex Differences in Rotenone Sensitivity Reflect the Male-to-Female Ratio in Human Parkinsonâ€™s Disease Incidence. Toxicological Sciences, 2019, 170, 133-143.	1.4	41
14	Phenothiazine normalizes the NADH/NAD+ ratio, maintains mitochondrial integrity and protects the nigrostriatal dopamine system in a chronic rotenone model of Parkinson's disease. Redox Biology, 2019, 24, 101164.	3.9	31
15	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.5	194
16	Spectrum of tau pathologies in Huntington's disease. Laboratory Investigation, 2019, 99, 1068-1077.	1.7	23
17	Long-term RNAi knockdown of Î±-synuclein in the adult rat substantia nigra without neurodegeneration. Neurobiology of Disease, 2019, 125, 146-153.	2.1	38
18	Astrocyte-specific DJ-1 overexpression protects against rotenone-induced neurotoxicity in a rat model of Parkinson's disease. Neurobiology of Disease, 2018, 115, 101-114.	2.1	83

#	Article	IF	Citations
19	RAD52 is required for RNA-templated recombination repair in post-mitotic neurons. Journal of Biological Chemistry, 2018, 293, 1353-1362.	1.6	69
20	Mitochondrial Complex I Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease. Antioxidants and Redox Signaling, 2018, 28, 44-61.	2.5	21
21	What's wrong with mitochondria in Parkinson's disease?. Movement Disorders, 2018, 33, 1515-1517.	2.2	7
22	New Frontiers in Parkinson's Disease: From Genetics to the Clinic. Journal of Neuroscience, 2018, 38, 9375-9382.	1.7	32
23	Newly Revised Quantitative PCRâ€Based Assay for Mitochondrial and Nuclear DNA Damage. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2018, 76, e50.	1.1	11
24	LRRK2 activation in idiopathic Parkinsonâ€™s disease. Science Translational Medicine, 2018, 10, .	5.8	363
25	Evidence for Compartmentalized Axonal Mitochondrial Biogenesis: Mitochondrial DNA Replication Increases in Distal Axons As an Early Response to Parkinson's Disease-Relevant Stress. Journal of Neuroscience, 2018, 38, 7505-7515.	1.7	51
26	Editorâ€™s Highlight: Base Excision Repair Variants and Pesticide Exposure Increase Parkinsonâ€™s Disease Risk. Toxicological Sciences, 2017, 158, 188-198.	1.4	31
27	Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cellular and Molecular Life Sciences, 2017, 74, 2851-2874.	2.4	94
28	LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinsonâ€™s disease. Human Molecular Genetics, 2017, 26, 4340-4351.	1.4	76
29	The Gordon Research Seminar & Conference on Parkinsonâ€™s disease: state of the Science 200 years after James Parkinsonâ€™s essay on the Shaking Palsy. Npj Parkinson's Disease, 2017, 3, .	2.5	0
30	Samay Jain, MD, June 2, 1974-September 8, 2016. Movement Disorders, 2016, 31, 1800-1801.	2.2	0
31	Î±-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinsonâ€™s disease. Science Translational Medicine, 2016, 8, 342ra78.	5.8	432
32	Folding Landscape of Mutant Huntingtin Exon1: Diffusible Multimers, Oligomers and Fibrils, and No Detectable Monomer. PLoS ONE, 2016, 11, e0155747.	1.1	48
33	shRNA targeting Î±-synuclein prevents neurodegeneration in a Parkinsonâ€™s disease model. Journal of Clinical Investigation, 2015, 125, 2721-2735.	3.9	143
34	LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease. Free Radical Research, 2015, 49, 681-691.	1.5	60
35	Post-translational modification of Î±-synuclein in Parkinson×³s disease. Brain Research, 2015, 1628, 247-253.	1.1	138
36	Fruit flies, bile acids, and Parkinson disease. Neurology, 2015, 85, 838-839.	1.5	9

#	ARTICLE	IF	CITATIONS
37	PCR Based Determination of Mitochondrial DNA Copy Number in Multiple Species. Methods in Molecular Biology, 2015, 1241, 23-38.	0.4	307
38	Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiology of Aging, 2015, 36, 505-518.	1.5	42
39	Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats. Neurobiology of Disease, 2015, 73, 356-365.	2.1	37
40	Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease. Neurobiology of Aging, 2014, 35, 1162-1176.	1.5	78
41	LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction. Neurobiology of Disease, 2014, 62, 381-386.	2.1	235
42	Mitochondrial DNA Damage as a Peripheral Biomarker for Mitochondrial Toxin Exposure in Rats. Toxicological Sciences, 2014, 142, 395-402.	1.4	23
43	Transient muscarinic and glutamatergic stimulation of neural stem cells triggers acute and persistent changes in differentiation. Neurobiology of Disease, 2014, 70, 252-261.	2.1	10
44	Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson's disease. Neurobiology of Disease, 2014, 70, 214-223.	2.1	155
45	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet, The, 2014, 384, 545-555.	6.3	336
46	A Rapid and Sensitive Automated Imageâ€Based Approach for In Vitro and In Vivo Characterization of Cell Morphology and Quantification of Cell Number and Neurite Architecture. Current Protocols in Cytometry, 2014, 68, 12.33.1-22.	3.7	16
47	Rotenone as Preclinical Model Compound in Parkinson Disease. , 2014, , 995-1012.		3
48	Geneâ€“environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models. Neurobiology of Disease, 2013, 57, 38-46.	2.1	158
49	Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro. Neurobiology of Disease, 2013, 54, 158-168.	2.1	41
50	Thiol oxidation and altered NR2B/NMDA receptor functions in in vitro and in vivo pilocarpine models: Implications for epileptogenesis. Neurobiology of Disease, 2013, 49, 87-98.	2.1	43
51	Expression of human E46K-mutated Î±-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Experimental Neurology, 2013, 240, 44-56.	2.0	61
52	Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radical Biology and Medicine, 2013, 62, 111-120.	1.3	275
53	DJ-1 Expression Modulates Astrocyte-Mediated Protection Against Neuronal Oxidative Stress. Journal of Molecular Neuroscience, 2013, 49, 507-511.	1.1	63
54	Toxin Models of Mitochondrial Dysfunction in Parkinson's Disease. Antioxidants and Redox Signaling, 2012, 16, 920-934.	2.5	206

#	ARTICLE	IF	CITATIONS
55	Hypokinesia and Reduced Dopamine Levels in Zebrafish Lacking Î²- and Î³1-Synucleins. Journal of Biological Chemistry, 2012, 287, 2971-2983.	1.6	71
56	Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1125-1136.	1.8	49
57	Regulation of complex I by Engrailed is complex too. Nature Neuroscience, 2011, 14, 1221-1222.	7.1	3
58	Single-Cell Redox Imaging Demonstrates a Distinctive Response of Dopaminergic Neurons to Oxidative Insults. Antioxidants and Redox Signaling, 2011, 15, 855-871.	2.5	70
59	Mouse ES cells overexpressing DNMT1 produce abnormal neurons with upregulated NMDA/NR1 subunit. Differentiation, 2011, 82, 9-17.	1.0	19
60	Autonomic insufficiency in pupillary and cardiovascular systems in Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2011, 17, 119-122.	1.1	36
61	Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Experimental Neurology, 2011, 228, 41-52.	2.0	56
62	Pilocapine alters NMDA receptor expression and function in hippocampal neurons: NADPH oxidase and ERK1/2 mechanisms. Neurobiology of Disease, 2011, 42, 482-495.	2.1	82
63	Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease. Movement Disorders, 2011, 26, 1344-1347.	2.2	17
64	Peroxiredoxin-2 Protects against 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration via Attenuation of the Apoptosis Signal-Regulating Kinase (ASK1) Signaling Cascade. Journal of Neuroscience, 2011, 31, 247-261.	1.7	136
65	The Role of Environmental Exposures in Neurodegeneration and Neurodegenerative Diseases. Toxicological Sciences, 2011, 124, 225-250.	1.4	334
66	Autophagy Protects Against Aminochrome-Induced Cell Death in Substantia Nigra-Derived Cell Line. Toxicological Sciences, 2011, 121, 376-388.	1.4	63
67	Mitochondrial Iron Metabolism and Its Role in Neurodegeneration. Journal of Alzheimer's Disease, 2010, 20, S551-S568.	1.2	159
68	Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents. Neurobiology of Disease, 2010, 38, 476-481.	2.1	26
69	Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. Journal of Neuroscience Research, 2010, 88, 420-427.	1.3	81
70	Geneâ€“Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling. Clinical Pharmacology and Therapeutics, 2010, 88, 467-474.	2.3	65
71	Lessons from the rotenone model of Parkinson's disease. Trends in Pharmacological Sciences, 2010, 31, 141-142.	4.0	127
72	Neurotoxic in vivo models of Parkinsonâ€™s disease. Progress in Brain Research, 2010, 184, 17-33.	0.9	164

#	Article	IF	Citations
73	Peroxidase Mechanism of Lipid-dependent Cross-linking of Synuclein with Cytochrome c. Journal of Biological Chemistry, 2009, 284, 15951-15969.	1.6	86
74	A highly reproducible rotenone model of Parkinson's disease. Neurobiology of Disease, 2009, 34, 279-290.	2.1	601
75	A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiology of Disease, 2009, 34, 417-431.	2.1	162
76	Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiology of Disease, 2009, 36, 96-102.	2.1	200
77	NeuN is not a reliable marker of dopamine neurons in rat substantia nigra. Neuroscience Letters, 2009, 464, 14-17.	1.0	52
78	In Vivo Labeling of Mitochondrial Complex I (NADH:UbiquinoneOxidoreductase) in Rat Brain Using [3H]Dihydrorotenone. Journal of Neurochemistry, 2008, 75, 2611-2621.	2.1	116
79	A FRET-based method to study protein thiol oxidation in histological preparations. Free Radical Biology and Medicine, 2008, 45, 971-981.	1.3	30
80	Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism. Neuroscience, 2008, 152, 198-207.	1.1	10
81	Complex I Inhibition, Rotenone and Parkinson's Disease. , 2008, , 195-206.		0
82	Protection by the NDI1 Gene against Neurodegeneration in a Rotenone Rat Model of Parkinson's Disease. PLoS ONE, 2008, 3, e1433.	1.1	94
83	Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease. Archives of Neurology, 2008, 65, 1582-9.	4.9	71
84	N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking. Journal of Neuroscience, 2008, 28, 2783-2792.	1.7	362
85	Huntingtonâ€™s Disease: Getting Closer. American Journal of Psychiatry, 2007, 164, 1318-1318.	4.0	4
86	Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 318-326.	1.3	97
87	Huntington's Disease â€” Making Connections. New England Journal of Medicine, 2007, 356, 518-520.	13.9	31
88	Obligatory Role for Complex I Inhibition in the Dopaminergic Neurotoxicity of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicological Sciences, 2007, 95, 196-204.	1.4	109
89	Parkinson's disease: animal models. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 265-287.	1.0	11
90	Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. Journal of Neurochemistry, 2007, 100, 070214184024016-???.	2.1	265

#	ARTICLE	IF	CITATIONS
91	Pink, parkin and the brain. Nature, 2006, 441, 1058-1058.	13.7	24
92	Update on huntingtonâ€™s disease. Current Neurology and Neuroscience Reports, 2006, 6, 281-286.	2.0	7
93	Protection against oxidant-induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblastoma cells. Toxicology and Applied Pharmacology, 2006, 216, 256-262.	1.3	30
94	Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, Î±-synuclein, and the ubiquitinâ€“proteasome system. Neurobiology of Disease, 2006, 22, 404-420.	2.1	313
95	Interrater agreement in the assessment of motor manifestations of Huntington's disease. Movement Disorders, 2005, 20, 293-297.	2.2	83
96	Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington?s disease individuals. Molecular and Cellular Biochemistry, 2005, 269, 143-152.	1.4	88
97	Mitochondria, metabolic inhibitors and neurodegeneration. , 2005, , 33-43.		0
98	Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial. Neurology, 2005, 65, 286-292.	1.5	143
99	Rotenone Model of Parkinson Disease. Journal of Biological Chemistry, 2005, 280, 42026-42035.	1.6	244
100	Oxidative Damage in Parkinson's Disease. Antioxidants and Redox Signaling, 2005, 7, 627-629.	2.5	24
101	Paraquat Neurotoxicity is Distinct from that of MPTP and Rotenone. Toxicological Sciences, 2005, 88, 193-201.	1.4	215
102	Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Molecular Brain Research, 2005, 134, 109-118.	2.5	227
103	Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiology of Disease, 2005, 18, 19-31.	2.1	160
104	Ubiquitinâ€“proteasome system and Parkinson's diseases. Experimental Neurology, 2005, 191, S17-S27.	2.0	198
105	Rotenone Rat and Other Neurotoxin Models of Parkinson Disease. , 2005, , 161-172.		0
106	BIOMEDICINE: Parkinson's--Divergent Causes, Convergent Mechanisms. Science, 2004, 304, 1120-1122.	6.0	391
107	Role of External Pallidal Segment in Primate Parkinsonism: Comparison of the Effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism and Lesions of the External Pallidal Segment. Journal of Neuroscience, 2004, 24, 6417-6426.	1.7	179
108	Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates. Annals of Neurology, 2004, 56, 723-727.	2.8	13

#	ARTICLE	IF	CITATIONS
109	Differential expression and ser897 phosphorylation of striatal N -methyl- d -aspartate receptor subunit NR1 in animal models of Parkinson's disease. Experimental Neurology, 2004, 187, 76-85.	2.0	32
110	Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Experimental Neurology, 2004, 189, 393-403.	2.0	30
111	Quantitative evaluation of the effects of mitochondrial permeability transition pore modifiers on accumulation of calcium phosphate: comparison of rat liver and brain mitochondria. Archives of Biochemistry and Biophysics, 2004, 424, 44-52.	1.4	56
112	Rotenone, Deguelin, Their Metabolites, and the Rat Model of Parkinson's Disease. Chemical Research in Toxicology, 2004, 17, 1540-1548.	1.7	175
113	Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and Î±-Synuclein Aggregation. Experimental Neurology, 2003, 179, 9-16.	2.0	599
114	In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntingtonâ€™s disease. Archives of Biochemistry and Biophysics, 2003, 410, 1-6.	1.4	94
115	Selective microglial activation in the rat rotenone model of Parkinson's disease. Neuroscience Letters, 2003, 341, 87-90.	1.0	283
116	The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism and Related Disorders, 2003, 9, 59-64.	1.1	207
117	Mechanism of Toxicity in Rotenone Models of Parkinson's Disease. Journal of Neuroscience, 2003, 23, 10756-10764.	1.7	887
118	Environment, Mitochondria, and Parkinson's Disease. Neuroscientist, 2002, 8, 192-197.	2.6	120
119	An<i>In Vitro</i>Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered Î±-Synuclein Metabolism and Oxidative Damage. Journal of Neuroscience, 2002, 22, 7006-7015.	1.7	547
120	Acute Mitochondrial and Chronic Toxicological Effects of 1-Methyl-4-Phenylpyridinium in Human Neuroblastoma Cells. NeuroToxicology, 2002, 23, 569-580.	1.4	28
121	Animal models of Parkinson's disease. BioEssays, 2002, 24, 308-318.	1.2	494
122	Exacerbation of NMDA, AMPA, and l-Glutamate Excitotoxicity by the Succinate Dehydrogenase Inhibitor Malonate. Journal of Neurochemistry, 2002, 64, 2332-2338.	2.1	68
123	Manipulation of Membrane Potential Modulates Malonate-Induced Striatal Excitotoxicity In Vivo. Journal of Neurochemistry, 2002, 66, 637-643.	2.1	49
124	Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience, 2002, 5, 731-736.	7.1	925
125	Mechanistic Approaches to Parkinson's Disease Pathogenesis. Brain Pathology, 2002, 12, 499-510.	2.1	115
126	Environment, Mitochondria, and Parkinsonâ€™s Disease. Neuroscientist, 2002, 8, 192-197.	2.6	116

#	ARTICLE	IF	CITATIONS
127	Chronic Complex I Inhibition Reproduces Features of Parkinsonâ€™s Disease. Advances in Behavioral Biology, 2002, , 271-276.	0.2	0
128	Response: Parkinson's disease, pesticides and mitochondrial dysfunction. Trends in Neurosciences, 2001, 24, 247.	4.2	18
129	Pesticides and Parkinsonâ€™s Disease. Scientific World Journal, The, 2001, 1, 207-208.	0.8	18
130	Glutamatergic Influences on the Basal Ganglia. Clinical Neuropharmacology, 2001, 24, 65-70.	0.2	80
131	Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. Neurological Sciences, 2001, 22, 49-50.	0.9	27
132	Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Annals of Neurology, 2001, 49, 525-529.	2.8	65
133	Complex I and Parkinson's Disease. IUBMB Life, 2001, 52, 135-141.	1.5	305
134	A randomized, controlled trial of remacemide for motor fluctuations in Parkinsonâ€™s disease. Neurology, 2001, 56, 455-462.	1.5	58
135	Immunocytochemical Characterization of the Mitochondrially Encoded ND1 Subunit of Complex I (NADH : Ubiquinone Oxidoreductase) in Rat Brain. Journal of Neurochemistry, 2000, 75, 383-392.	2.1	25
136	GluR1 Glutamate Receptor Subunit Is Regulated Differentially in the Primate Basal Ganglia Following Nigrostriatal Dopamine Denervation. Journal of Neurochemistry, 2000, 74, 1166-1174.	2.1	58
137	Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience, 2000, 3, 1301-1306.	7.1	3,216
138	Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity. Journal of Biological Chemistry, 2000, 275, 26096-26101.	1.6	228
139	Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-d-Aspartate Receptors. Experimental Neurology, 2000, 163, 239-243.	2.0	124
140	"Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology. Functional Neurology, 2000, 15, 67-80.	1.3	5
141	Mitochondrial dysfunction in Parkinson's disease. Biochemical Society Symposia, 1999, 66, 85-97.	2.7	227
142	Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nature Medicine, 1999, 5, 1194-1198.	15.2	516
143	Ca2+-Dependent Permeability Transition and Complex I Activity in Lymphoblast Mitochondria from Normal Individuals and Patients with Huntington's or Alzheimer's Disease. Annals of the New York Academy of Sciences, 1999, 893, 365-368.	1.8	22
144	Synthesis and evaluation of a new fluorine-18 labeled rotenoid as a potential PET probe of mitochondrial complex I activity. Journal of Labelled Compounds and Radiopharmaceuticals, 1999, 42, 1039-1051.	0.5	10

#	ARTICLE	IF	CITATIONS
145	Differential Expression of Glutamate Receptors by the Dopaminergic Neurons of the Primate Striatum. Experimental Neurology, 1999, 159, 401-408.	2.0	25
146	Prospects of glutamate antagonists in the therapy of Parkinson's disease. Fundamental and Clinical Pharmacology, 1998, 12, 4-12.	1.0	41
147	Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. Movement Disorders, 1998, 13, 11-15.	2.2	41
148	3-Nitropropionic acid exacerbates N-methyl-d-aspartate toxicity in striatal culture by multiple mechanisms. Neuroscience, 1998, 84, 503-510.	1.1	77
149	Visualization of NMDA Receptor-Induced Mitochondrial Calcium Accumulation in Striatal Neurons. Experimental Neurology, 1998, 149, 1-12.	2.0	108
150	Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors. Molecular Pharmacology, 1998, 53, 974-80.	1.0	146
151	Lead-induced changes in NMDA receptor complex binding: correlations with learning accuracy and with sensitivity to learning impairments caused by MK-801 and NMDA administration. Behavioural Brain Research, 1997, 85, 161-174.	1.2	45
152	Dopaminergic Neurons Intrinsic to the Primate Striatum. Journal of Neuroscience, 1997, 17, 6761-6768.	1.7	244
153	Subthalamic Ablation Reverses Changes in Basal Ganglia Oxidative Metabolism and Motor Response to Apomorphine Induced by Nigrostriatal Lesion in Rats. European Journal of Neuroscience, 1997, 9, 1407-1413.	1.2	55
154	Intrastriatal Neurotoxin Injections Reduce in Vitro and in Vivo Binding of Radiolabeled Rotenoids to Mitochondrial Complex I. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 265-272.	2.4	13
155	Susceptibility of Adult Rats to Lead-induced Changes in NMDA Receptor Complex Function. Neurotoxicology and Teratology, 1997, 19, 517-530.	1.2	9
156	Bioenergetics and glutamate excitotoxicity. Progress in Neurobiology, 1996, 48, 613-634.	2.8	225
157	ARL-15896, a NovelN-Methyl-D-aspartate Receptor Ion Channel Antagonist: Neuroprotection against Mitochondrial Metabolic Toxicity and Regional Pharmacology. Experimental Neurology, 1996, 137, 66-72.	2.0	19
158	[³H]Dihydrorotenone Binding to NADH: Ubiquinone Reductase (Complex I) of the Electron Transport Chain: An Autoradiographic Study. Journal of Neuroscience, 1996, 16, 3807-3816.	1.7	95
159	Glutamate and Parkinsonâ€™s disease. Molecular Neurobiology, 1996, 12, 73-94.	1.9	296
160	Coexistence of Huntington's disease and familial amyotrophic lateral sclerosis: case presentation. Acta Neuropathologica, 1996, 92, 421-427.	3.9	28
161	A controlled trial of remacemide hydrochloride in Huntington's disease. Movement Disorders, 1996, 11, 273-277.	2.2	100
162	Pharmacological pallidotomy with glutamate antagonists?. Annals of Neurology, 1996, 39, 557-558.	2.8	17

#	ARTICLE	IF	CITATIONS
163	Bioenergetics and excitotoxicity. , 1996, , 125-142.		3
164	The role of glutamate in the pathophysiology of Parkinson's disease. Functional Neurology, 1996, 11, 3-15.	1.3	51
165	Assay of [3H] Dihydrorotenone Binding to Complex I in Intact Human Platelets. Analytical Biochemistry, 1995, 230, 16-19.	1.1	11
166	Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia. Brain Research, 1995, 669, 59-66.	1.1	32
167	Sprouting of dopaminergic fibers from spared mesencephalic dopamine neurons in the unilateral partial lesioned rat. Brain Research, 1995, 670, 197-204.	1.1	38
168	Intrastriatal injections of the succinate dehydrogenase inhibitor, malonate, cause a rise in extracellular amino acids that is blocked by MK-801. Brain Research, 1995, 684, 221-224.	1.1	29
169	Selective vulnerability of the CA1 region of hippocampus to the indirect excitotoxic effects of malonic acid. Neuroscience Letters, 1995, 192, 29-32.	1.0	39
170	Chronic treatment with thioctic acid does not protect against malonate toxicity in vivo. Neuroscience Letters, 1995, 196, 125-127.	1.0	2
171	Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion. Neuroscience Letters, 1995, 186, 99-102.	1.0	15
172	Characterization of the Excitotoxic Potential of the Reversible Succinate Dehydrogenase Inhibitor Malonate. Journal of Neurochemistry, 1995, 64, 430-436.	2.1	107
173	Regional Variations in the Pharmacology of NMDA Receptor Channel Blockers: Implications for Therapeutic Potential. Journal of Neurochemistry, 1995, 64, 614-623.	2.1	128
174	Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. Journal of Neuroscience, 1994, 14, 7192-7199.	1.7	118
175	Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Annals of Neurology, 1994, 35, 655-661.	2.8	150
176	Regional variations in the pharmacology of AMPA receptors as revealed by receptor autoradiography. Brain Research, 1994, 664, 202-206.	1.1	17
177	The endogenous cofactors, thioctic acid and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum. Neuroscience Letters, 1994, 171, 17-20.	1.0	61
178	Inhibition of autoradiographic MK-801 binding by an endogenous factor. Neuroscience Letters, 1994, 169, 105-108.	1.0	11
179	Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an "Excitotoxic" Lesion in Rat Striatum. Journal of Neurochemistry, 1993, 61, 1151-1154.	2.1	210
180	NMDA and AMPA Receptors in Transgenic Mice Expressing HumanÎ²-Amyloid Protein. Journal of Neurochemistry, 1993, 61, 2286-2289.	2.1	16

#	ARTICLE	IF	CITATIONS
181	Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. Journal of Neural Transmission, 1993, 91, 255-269.	1.4	127
182	Neurotransmitter receptors in Alzheimer disease. Cerebrovascular and Brain Metabolism Reviews, 1993, 5, 61-94.	2.0	18
183	N-Methyl-D-Aspartate Antagonists, Schizophrenia, and Neuroleptic Malignant Syndrome-Reply. Archives of Neurology, 1992, 49, 901-901.	4.9	1
184	Alternative excitotoxic hypotheses. Neurology, 1992, 42, 733-733.	1.5	566
185	Quantitative Autoradiography of Dihydrorotenone Binding to Complex I of the Electron Transport Chain. Journal of Neurochemistry, 1992, 59, 746-749.	2.1	38
186	Neuronal bioenergetic defects, excitotoxicity and Alzheimer's disease: â€œUse it and lose itâ€. Neurobiology of Aging, 1991, 12, 334-336.	1.5	31
187	A study of cortical and hippocampal NMDA and PCP receptors following selective cortical and subcortical lesions. Brain Research, 1991, 538, 36-45.	1.1	14
188	The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Annals of Neurology, 1991, 30, 717-723.	2.8	251
189	N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease. Archives of Neurology, 1991, 48, 977-981.	4.9	227
190	Excitotoxicity and Dopaminergic Dysfunction in the Acquired Immunodeficiency Syndrome Dementia Complex. Archives of Neurology, 1991, 48, 1281.	4.9	74
191	Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 314-320.	0.9	92
192	Regional ontogeny of a unique glutamate recognition site in rat brain: An autoradiographic study. International Journal of Developmental Neuroscience, 1990, 8, 437-445.	0.7	20
193	Spectrophotometric determination of refractive index increment for bacterial cells. Journal of Microbiological Methods, 1990, 11, 255-260.	0.7	1
194	Sodium-dependentd-aspartate â€˜bindingâ€™ is not a measure of presynaptic neuronal uptake sites in an autoradiographic assay. Brain Research, 1990, 511, 310-318.	1.1	34
195	Contamination of commercially available quisqualic acid by glutamate-like and aspartate-like substances. Journal of Neuroscience Methods, 1989, 27, 143-148.	1.3	8
196	Authors' response to commentaries. Neurobiology of Aging, 1989, 10, 618-620.	1.5	16
197	Synaptic localization of striatal NMDA, quisqualate and kainate receptors. Neuroscience Letters, 1989, 101, 133-137.	1.0	90
198	Excitatory amino acids and Alzheimer's disease. Neurobiology of Aging, 1989, 10, 593-602.	1.5	489

#	ARTICLE	IF	CITATIONS
199	Properties of Quisqualate-Sensitive L-[3H]Glutamate Binding Sites in Rat Brain as Determined by Quantitative Autoradiography. Journal of Neurochemistry, 1988, 51, 469-478.	2.1	57
200	Glutamate transmission and toxicity in alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12, 421-IN4.	2.5	155
201	Glutamate recognition sites in human fetal brain. Neuroscience Letters, 1988, 84, 131-136.	1.0	63
202	NMDA receptor losses in putamen from patients with Huntington's disease. Science, 1988, 241, 981-983.	6.0	380
203	Glutamate dysfunction in Alzheimer's disease: an hypothesis. Trends in Neurosciences, 1987, 10, 65-68.	4.2	313
204	Autoradiographic localization of cerebellar excitatory amino acid binding sites in the mouse. Neuroscience, 1987, 22, 913-923.	1.1	82
205	Dementia of the Alzheimer's Type: Changes in Hippocampal L-[3H]Glutamate Binding. Journal of Neurochemistry, 1987, 48, 543-551.	2.1	274
206	High correlation between the localization of [3H]TCP binding and NMDA receptors. European Journal of Pharmacology, 1986, 123, 173-174.	1.7	120
207	The Role of Glutamate in Neurotransmission and in Neurologic Disease. Archives of Neurology, 1986, 43, 1058-1063.	4.9	292
208	Glutamate Receptors and Glutamate Corticofugal Pathways. , 1986, , 355-365.		0
209	Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. Science, 1985, 227, 1496-1499.	6.0	331
210	Autoradiographic characterization of N-methyl-D-aspartate-, quisqualate- and kainate-sensitive glutamate binding sites. Journal of Pharmacology and Experimental Therapeutics, 1985, 233, 254-63.	1.3	235
211	Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system. Journal of Neuroscience, 1984, 4, 2133-2144.	1.7	332
212	Quantitative autoradiography of L-[3H]glutamate binding to rat brain. Neuroscience Letters, 1983, 37, 155-160.	1.0	48